ESR1 and breast carcinoma: Particularly in breast cancer, Murrow et al. used a RNAi screen of the human tyrosine kinome, to identify WEE1 as a potential therapeutic target in triple-negative breast cancer cells that lack ER, progesterone receptor [PR] or HER2 (27).